Onchilles Pharma Receives FDA Clearance for First-in-Class ELANE Pathway Cancer Therapeutic N17350
核心洞察
Onchilles Pharma (搜索) announced FDA IND clearance for N17350, the first next-generation cytotoxic therapeutic leveraging the ELANE (搜索) pathway for advanced solid tumors (搜索).
N17350 demonstrated consistent efficacy across dozens of cancer cell lines and in vivo models, including chemotherapy-resistant and immunologically "cold" tumors.
The first-in-human study will evaluate N17350 as monotherapy in patients with melanoma (搜索), head and neck cancers, lung cancer, and triple-negative breast cancer.
Onchilles Pharma (搜索) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for N17350, enabling the company to initiate first-in-human clinical studies in patients with advanced solid tumors (搜索). The San Diego-based biotech company is pioneering next-generation cytotoxic therapeutics that harness the ELANE (搜索) pathway, an innate immune mechanism that selectively kills cancer cells while preserving and activating the immune system.
Novel Mechanism Targets Cancer Cell Vulnerability
N17350 represents a first-in-class tumor-directed therapeutic candidate that leverages the ELANE (搜索) pathway by targeting a vulnerability shared by many cancer cell types: elevated histone H1 (搜索) levels. According to Lev Becker, Ph.D., Co-Founder and Chief Scientific Officer of Onchilles Pharma (搜索), the mechanism "broadly kills cancer cells while preserving and activating immune cells, thereby transforming cancer cell death into long-lasting anti-tumor immunity."
The therapeutic approach differs fundamentally from traditional cytotoxic chemotherapies or immunotherapies by offering a cancer-selective mechanism designed to eliminate tumors while simultaneously training the immune system to respond.
Robust Preclinical Efficacy Data
N17350 demonstrated consistent efficacy in preclinical models spanning dozens of cancer cell lines, patient-derived samples, and multiple in vivo models. Notably, the therapeutic showed activity against chemotherapy-resistant and immunologically "cold" tumors, where it induced immunogenic cancer cell death and drove CD8+ T cell (搜索)-mediated immune activation.
"The preclinical data supporting N17350 suggest a mechanism that kills tumors and simultaneously primes the immune system," said Alain P. Algazi, M.D., Onchilles N17350 Clinical Advisory Board Chair and Director, Program Leader, UCSF Head and Neck Medical Oncology. "If this dual activity translates clinically, it could represent a meaningful advance for patients with tumors that are difficult to treat with existing cytotoxic or immunotherapy approaches."
Clinical Trial Design and Patient Population
The first-in-human study will evaluate the safety, tolerability, and preliminary clinical activity of N17350 as a monotherapy in patients with advanced solid tumors (搜索). The trial will include patients with melanoma (搜索), head and neck neoplasms (搜索), squamous cell carcinoma (搜索) of skin, non-small-cell lung carcinoma (搜索), and triple-negative breast neoplasms (搜索) (ClinicalTrials.gov Identifier: NCT07339176 (搜索)).
The study is designed to assess pharmacodynamic biomarkers associated with ELANE (搜索) pathway engagement and immune activation, providing early clinical insight into the mechanism. Onchilles plans to initiate first-in-human dosing at multiple sites in the United States and Australia.
Broader Pipeline Development
Beyond N17350, Onchilles Pharma (搜索)'s pipeline includes the NEU-002 program for systemic delivery, which extends the reach of the ELANE (搜索) pathway approach to address all solid tumors. The company's therapeutic programs are designed to treat cancer regardless of genetic makeup, anatomical origin, or immune status.
Court R. Turner, J.D., Co-Founder and Chief Executive Officer of Onchilles Pharma (搜索), emphasized that the approach "has the potential to address unmet needs across many different tumor types" as the company advances into clinical testing. The ELANE (搜索) pathway mechanism is positioned to overcome limitations of current treatment paradigms by offering both potent tumor cell destruction and sustained immune activation.